Published in Mol Ther on February 01, 2005
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab (2008) 1.35
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics (2009) 1.20
Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer (2009) 1.17
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther (2007) 1.14
The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J Virol (2009) 1.09
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One (2010) 0.95
Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice. PLoS One (2012) 0.93
Effective oncolytic vaccinia therapy for human sarcomas. J Surg Res (2011) 0.92
Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther (2009) 0.92
Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression. Oncotarget (2014) 0.91
Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J Virol (2008) 0.90
Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol (2008) 0.86
A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China. PLoS One (2012) 0.86
Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-β. Viral Immunol (2011) 0.84
Cellular unfolded protein response against viruses used in gene therapy. Front Microbiol (2014) 0.83
Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol (2014) 0.82
CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans. J Immunol (2013) 0.82
Fighting cancer with oncolytic viruses. BMJ (2006) 0.82
Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. J Exp Clin Cancer Res (2014) 0.80
Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med (2014) 0.80
Orthopox Viruses: Infections in Humans. Transfus Med Hemother (2010) 0.79
B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals. Virology (2006) 0.78
Oncolytic vaccinia virus therapy of salivary gland carcinoma. JAMA Otolaryngol Head Neck Surg (2013) 0.78
A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. J Exp Clin Cancer Res (2014) 0.78
A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther (2009) 0.77
Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus. Head Neck (2015) 0.76
The N-terminus of vaccinia virus host range protein C7L is essential for function. Virus Genes (2012) 0.75
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol (2007) 2.26
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther (2005) 1.81
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest (2004) 1.51
Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther (2008) 1.51
mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther (2005) 1.46
Oncolytic viral therapies. Cancer Gene Ther (2004) 1.26
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc (2012) 1.19
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
GM-CSF gene-transduced tumor vaccines. Mol Ther (2005) 1.16
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
RNA interference and cancer therapy. Pharm Res (2011) 1.11
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther (2013) 1.08
Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther (2010) 1.05
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol (2005) 1.02
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res (2006) 1.02
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res (2004) 1.00
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res (2011) 0.99
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol (2011) 0.99
Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther (2008) 0.99
Head and neck cancer: response to p53-based therapeutics. Head Neck (2011) 0.98
Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc (Bayl Univ Med Cent) (2008) 0.96
PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer (2010) 0.94
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol (2008) 0.94
MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma. Cancer Invest (2012) 0.94
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther (2011) 0.93
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer (2009) 0.93
Potential use of RNA interference in cancer therapy. Expert Rev Mol Med (2010) 0.93
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet (2009) 0.92
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol (2012) 0.92
p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther (2007) 0.91
Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther (2005) 0.90
A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther (2009) 0.90
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J Gene Med (2010) 0.90
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res (2007) 0.90
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol (2002) 0.89
Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets (2012) 0.89
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One (2012) 0.88
Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc (Bayl Univ Med Cent) (2010) 0.88
Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res (2006) 0.87
Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Rev Anticancer Ther (2007) 0.86
Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther (2003) 0.85
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol (2011) 0.85
RNA interference and personalized cancer therapy. Discov Med (2013) 0.83
Hereditary Inclusion Body Myopathy (HIBM2). Gene Regul Syst Bio (2009) 0.82
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome. Future Oncol (2008) 0.81
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
Multifunctional vaccines in cancer: the 'triad' approach. Expert Rev Vaccines (2011) 0.80
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr Gene Ther (2009) 0.79
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2). Gene Regul Syst Bio (2008) 0.79
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol (2012) 0.77
Overview of the development of personalized genomic medicine and surgery. World J Surg (2011) 0.77
Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer. Clin Lung Cancer (2003) 0.77
Current vaccine updates for lung cancer. Expert Rev Vaccines (2010) 0.77
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2015) 0.77
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. Gene Regul Syst Bio (2009) 0.76
Letter to the editor: Does dicer expression affect shRNA processing? Gene Regul Syst Bio (2009) 0.75
Individualised cancer therapeutics: dream or reality? Expert Opin Ther Targets (2005) 0.75
Defining the cancer master switch. World J Surg (2011) 0.75
Emergency use regulatory approval process for experimental gene-based therapy. J Clin Oncol (2008) 0.75
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. J Pediatr Hematol Oncol (2017) 0.75
Bacteria in the treatment of cancer. Curr Opin Mol Ther (2004) 0.75
Individualised cancer therapeutics: dream or reality? Therapeutics construction. Expert Opin Biol Ther (2005) 0.75
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application. Methods Mol Biol (2013) 0.75